Overexpression of BCL2 in 73% of BCas, with 86% in estrogen receptor-positive (ER+) tumors [19], nominates BCa as the first non-hematologic cancer type to be targeted with BCL2 inhibitors. The gene discussed is ESR1; the disease is cancer.